<DOC>
	<DOC>NCT02343939</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib (GS-9973) when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).</brief_summary>
	<brief_title>Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Key Adults with AML in need of treatment (except individuals with acute promyelocytic leukemia M3) Group A: Individuals &gt; 18 years of age with previously untreated AML who are able to receive cytarabine amd daunorubicin (7+3) chemotherapy as determined by the treating physician Group B: Individuals &gt; 70 years of age with previously untreated AML or individuals &lt; 70 years of age with previously untreated AML who refuse or are unable to receive cytarabine as determined by the treating physician Group C: Individuals &gt; 18 years of age with relapsed or refractory AML by WHO criteria or individuals with previously untreated AML who would have met eligibility criteria for Groups A or B but refuse or are unable to receive chemotherapy as determined by the treating physician Key Known active central nervous system or leptomeningeal lymphoma NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>